Jae Young Joung - Publications, H-index & Citations

Back

Jae Young Joung

national cancer center - korea (ncc)

20H-index

134Paper Count

2.7KCitation Count

Published Papers 40

Publication Date

Prognostic and Therapeutic Potential of Nicotinamide N-Methyltransferase and Hypoxia Inducible Lipid Droplet Associated in Clear Cell Renal Cell Carcinoma

Journal of Korean Medical Science

IF2.3

2025-12-15

OAAI

Kim, Mingyu; Song, Geehyun; Joung, Jae Young; Seo, Ho Kyung; Lee, Hyung Ho; Chung, Jinsoo

Save

Long-Term Cancer Incidence Trends in Korea (2001-2020): An Age-Period-Cohort and Joinpoint Analysis with a Focus on Younger Cohorts

MEDICINA-LITHUANIA

IF2.4

2025-12-08

OAAI

Lee, Hyungho; Kim, Mingyu; Song, Geehyun; Joung, Jae Young; Seo, Hokyung; Yoon, Jin-Ha; Chung, Jinsoo

Save

Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]

European Journal of Cancer

IF7.1

2025-11-13

PREAI

Arun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal

Save

Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer

European Urology Oncology

IF9.3

2025-11-04

OAAI

Fred Saad; Andrew J. Armstrong; Mototsugu Oya; Neal Shore; Giuseppe Procopio; João Daniel Guedes; Cagatay Arslan; Niven Mehra; Emma Brown; Jae Young Joung; Mikio Sugimoto; Oliver Sartor; Christian Poehlein; Elizabeth A. Harrington; Jinyu Kang; Noel Clarke

Save

Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions

Cancers 2025, Vol. 17, Page 3330

IF0

2025-10-15

OAAI

Whi-An Kwon; Jae Young Joung

Save

CDCA8 and TROAP as Prognostic Biomarkers of Postoperative Metastatic Progression in Clear Cell Renal Cell Carcinoma

Cancers 2025, Vol. 17, Page 2975

IF0

2025-09-23

OAAI

Mingyu Kim; Geehyun Song; Jaeyoung Joung; Hokyung Seo; Hyungho Lee; Jinsoo Chung

Save

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

lancet

IF0

2025-07-16

PREAI

Karim Fizazi; Arun A Azad; Nobuaki Matsubara; Joan Carles; André P Fay; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Matko Kalac; A Douglas Laird; Dana Kennedy; Neeraj Agarwal

Save

Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial

European Urology Oncology

IF9.3

2024-10-01

OAAI

Noel W. Clarke; Andrew J. Armstrong; Mototsugu Oya; Neal Shore; Giuseppe Procopio; João Daniel Guedes; Cagatay Arslan; Niven Mehra; Francis Parnis; Emma Brown; Friederike Schlürmann; Jae Young Joung; Mikio Sugimoto; Oliver Sartor; Christian Poehlein; David McGuinness; Arnold Degboe; Fred Saad

Save

Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Agarwal, N.; Azad, A. A.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Szczylik, C.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Oldenburg, J.; Lin, X.; Laird, D.; Kalac, M.; Kennedy, D.; Fizazi, K.

Save

Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Azad, A. A.; Agarwal, N.; Shore, N. D.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Saad, F.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Zschaebitz, S.; Piulats Rodriguez, J. M.; Yip, S. M.; Liu, G.; DeAnnuntis, L.; Lin, X.; Laird, D.; Kalac, M.; Fizazi, K.

Save

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

FUTURE ONCOLOGY

IF2.6

2024-07-12

OAAI

Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; Giorgi, Ugo De; Joung, Jae Young; Fong, Peter C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim

Save

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial (vol 30, pg 257, 2024)

NATURE MEDICINE

IF50

2024-01-31

OAAI

Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj

Save

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

NATURE MEDICINE

IF50

2023-12-04

OAAI

Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj

Save

Efficacy of olaparib (ola) plus abiraterone (abi) vs placebo (pbo) plus abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Mehra, N.; Clarke, N. W.; Armstrong, A. J.; Oya, M.; Shore, N. D.; Procopio, G.; Guedes, J. D. C.; Arslan, C.; Parnis, F.; Brown, E.; Schlurmann, F.; Joung, J. Y.; Sugimoto, M.; Choi, Y. D.; Castellano, D.; Urun, Y.; Hosius, C.; Desai, C.; Degboe, A.; Saad, F.

Save

Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Matsubara, N.; Fizazi, K.; Azad, A. A.; Galceran, J. Carles; Fay, A. P.; De Giorgi, U. F. F.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Karsh, L. I.; Barthelemy, P.; Lin, X.; Healy, C. G.; Di Santo, N.; Zohren, F.; Agarwal, N.

Save

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

LANCET

IF88.5

2023-07-01

181

PREAI

Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim

Save

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial

ASIAN JOURNAL OF ANDROLOGY

IF2.7

2023-06-06

OAAI

Chung, Byung Ha; Huang, Jian; Uemura, Hiroji; Choi, Young Deuk; Ye, Zhang-Qun; Suzuki, Hiroyoshi; Kang, Taek Won; He, Da-Lin; Joung, Jae Young; Brookman-May, Sabine D.; McCarthy, Sharon; Bhaumik, Amitabha; Singh, Anildeep; Mundle, Suneel; Chowdhury, Simon; Agarwal, Neeraj; Ye, Ding-Wei; Chi, Kim N.; Uemura, Hirotsugu

Save

Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study

JOURNAL OF UROLOGY

IF6.8

2023-01-01

OAAI

Lee, Hye Won; Lee, Hyung Ho; Park, Eun Young; Park, Weon Seo; Kim, Sung Han; Joung, Jae Young; Chung, Jinsoo; Seo, Ho Kyung

Save

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study

EUROPEAN JOURNAL OF CANCER

IF7.1

2022-07-01

OAAI

Roubaud, Guilhem; Oezgueroglu, Mustafa; Penel, Nicolas; Matsubara, Nobuaki; Mehra, Niven; Kolinsky, Michael P.; Procopio, Giuseppe; Feyerabend, Susan; Joung, Jae Young; Gravis, Gwenaelle; Nishimura, Kazuo; Gedye, Craig; Padua, Charles; Shore, Neal; Thiery-Vuillemin, Antoine; Saad, Fred; van Alphen, Robbert; Carducci, Michael A.; Desai, Chintu; Brickel, Neil; Poehlein, Christian; Del Rosario, Paula; Fizazi, Karim

Save

Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Chung, B. H.; Huang, J.; Uemura, H.; Choi, Y. D.; Ye, Z.; Suzuki, H.; Kang, T. W.; He, D.; Joung, J. Y.; Brookman-May, S. D.; McCarthy, S.; Bhaumik, A.; He, J.; Mundle, S. D.; Chowdhury, S.; Agarwal, N.; Ye, D.; Chi, K. N.; Uemura, H.

Save

Research Directions